Pravastatin prevents the progression of accelerated coronary artery disease after heart transplantation in a rabbit model.

Abstract

This study was designed to investigate the effects of pravastatin (Pr) on accelerated coronary arteriosclerosis in transplanted hearts. The rabbit hearts were transplanted to the recipients' neck heterotopically, and received FK506. The rabbits in group 1 were fed a normal diet (ND), and cholesterol-rich diet (CD) in group 2 and 3. Pr (10 mg/kg) was given to group 3. They were sacrificed at 4 weeks and the severity of myocardial rejection and arterio-sclerosis was assessed and scored histologically. The serum lipid levels were significantly elevated by a CD. However, addition of Pr had no effect on the levels of LDL and total cholesterol (TC). There was no significant difference in myocardial rejection in each group. Transplanted hearts in group 2 showed more severe arteriosclerotic lesions than those in group 1. Pr treatment in group 3 diminished the severity of coronary arteriosclerosis. Pr may prevent the accelerated coronary arteriosclerosis after heart transplantation without significant changes in TC and LDL.

• Authors: N Ogawa, I Koyama, T Shibata, T Watanabe, N Akimoto, Y Taguchi, N Shinozuka, R Omoto
• Journal: Transplant international : official journal of the European Society for Organ Transplantation (Transpl Int) Vol. 9 Suppl 1 Pg. S226-9 ( 1996) ISSN: 0934-0874 [Print] Switzerland
• PMID: 8959834 (Publication Type: Journal Article)

Chemical References

• Anticholesteremic Agents
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipids
• Pravastatin

Topics

• Animals
• Anticholesteremic Agents (therapeutic use)
• Coronary Artery Disease (prevention & control)
• Graft Rejection
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipids (blood)
• Liver Transplantation (adverse effects)
• Male
• Pravastatin (therapeutic use)
• Rabbits